Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced today the completion of its' pivotal Phase 2b clinical study of its oral insulin capsule, ORMD-0801. The Company expects to report results from this study within the coming weeks.
The Phase 2b trial is a randomized, double-blind, placebo-controlled, multi-centered study, that primary evaluated the safety, and tolerability of Oramed's oral insulin delivery technology. The study took place in five locations throughout South Africa and was monitored by OnQ Consulting, a clinical research organization (CRO) based in Johannesburg, South Africa.
"The completion of the Phase 2b clinical trial for ORMD-0801 is a significant milestone for Oramed," said Nadav Kidron, Chief Executive Officer of the Company, who continued, "We are especially thankful for the dedication of all the investigators who participated in the study."